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Background: The performance of zotarolimus-eluting stents (Medtronic Inc., Santa
Clara, CA, USA) versus other limus-eluting stents (LES) and the possible improvements
of Resolute zotarolimus-eluting stents (R-ZES) versus Endeavor zotarolimus-eluting
stents (E-ZES) still remain to be defined. We sought to evaluate efficacy and safety of two
zotarolimus-eluting stent generations versus other LES and to compare R-ZES versus
E-ZES.
Methods: We undertook a meta-analysis of trials in which patients were randomly
assigned to percutaneous coronary interventions (PCI) with R-ZES versus LES or with
E-ZES versus LES as well as an indirect comparison of R-ZES versus E-ZES, with LES
as common comparator. The primary efficacy endpoint was ischemia-driven target vessel
revascularization (ID-TVR); the primary safety endpoints were cardiac death and
cumulative definite/probable stent thrombosis (ST).
Results: Overall, 13,709 patients were assigned to PCI with R-ZES versus LES (n
7,185) or with E-ZES versus LES (n 6,524). The risk of ID-TVR (odds ratio [95%
confidence interval] 1.06 [0.90-1.25], p 0.47), cardiac death (0.99 [0.69-1.42], p
0.96) and ST (1.18 [0.68-2.03], p 0.56) did not differ between R-ZES and LES. Patients
receiving E-ZES were more likely to undergo ID-TVR as compared to those receiving
LES (1.95 [1.40-2.73], p0.0001). Cardiac death (1.02 [0.54-1.91], p 0.96) and ST
(1.10 [0.50-2.44], p 0.81) were similar between E-ZES and LES. At indirect compar-
ison, PCI with R-ZES versus E-ZES reduced the risk of ID-TVR (0.54 [0.37-0.78], p
0.001), without increasing cardiac death (0.97 [0.46-2.00], p 0.93) and ST (1.07
[0.40-2.80], p 0.88).
Conclusions: The antirestenotic efficacy of Resolute zotarolimus-eluting stents is
superior to Endeavor zotarolimus-eluting stents and similar to other limus-eluting stents.
Endeavor zotarolimus-eluting stents increase the risk of reinterventions as compared to
other limus-eluting stents. First and second zotarolimus-eluting stent generations have
similar thrombogenicity compared to other limus-eluting stents.
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Background: Vascular Inflammation plays a fundamental role in the process of
neointimal formation following coronary stent implantation. Drug-eluting stents (DES)
improve the efficacy of percutaneous coronary intervention by modulating vascular
inflammation. We aimed to evaluate the vascular inflammation profile following coronary
implantation of a novel stent comprising an abluminal biodegradable Everolimus-eluting
coating on the Element stent platform (SYNERGY) compared to an identical bare metal
stent control (BMS Element stent).
Methods: BMS (Element, n6) and SYNERGY (n6) stents were implanted in nine
8-month-old FH swine. Each coronary target site was predilated with an angioplasty
balloon prior to stent placement. At 30 days stents were analyzed with optical coherence
tomography (OCT) and then harvested for histological analysis and immunohistochem-
istry (MAC387: Macrophages; CD3: T-cells lymphocytes). Para strut leukocyte (PSL),
Foamy macrophage infiltration (FMI) and adventitial inflammation (AI) were evaluated in
a semi-quantitative score.
Results: Both OCT (neointimal area; SYNERGY, 3.680.8 mm2 vs. BMS, 5.70.8
mm2, 35% reduction) and histology (neointimal area; SYNERGY3.180.73 mm2 vs.
BMS 5.930.78 mm2, 46% reduction) demonstrated a significant reduction in
neointimal proliferation in the SYNERGY group. The SYNERGY stent exhibited
significant reduction in PSL (0.330.69) compared to BMS (2.390.7, p0.001). The
neointimal area occupied by foam cells was significantly greater in BMS (0.570.53
mm2) compared to SYNERGY group (0.280.35 mm2). Consistently, FMI score was
also decreased in SYNERGY (0.830.79) compared to BMS (2.442.06, p0.001). The
AI score, did not showed significant differences between the studied groups (SYNERGY
1.331.46, BMS 1.941.55; p0.15).
Conclusions: The abluminal-only Everolimus eluting SYNERGY stent demonstrated
suppression of neointimal formation and vascular inflammatory response compared to an
identical bare metal stent platform. The absence of polymer beyond the drug delivery
period creates the potential to reduce DAPT duration while maintaining best-in-class DES
efficacy.
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Background: Elderly patients (P) after bare metal stents (BMS) traditionally experience
higher rates of procedural complication and worse long-term outcomes compared to
younger P. This study sought to evaluate the long-term clinical follow-up (FU) after drug
elution stents (DES) in octogenarians compared to P60 y old and P 60-79 y old.
Methods: 4229 P were included in the DESIRE (Drug Elution Stents In The Real World)
Registry for an elective DES implantation between 05/2002 and 02/2012. They were
divided into 3 groups (g) according to their age: GI : 60 y (n;1,516 pts); GII:60-79 y
(n 2,397 pts); GIII:80 Y(n316 pts). The baseline and procedural characteristics as
well as the outcomes are in the table.














Mean age (y) 52,29 69,23 84,25 N/A
Female (%) 14,1 26* 43,3* 0.01
Diabetes (%) 24,6 34,8* 26,3 0.01
AMI Prior (%) 23,4 22,4 20,9 0.09
Hypertension (%) 69,3* 80,5 81,6 0.01
Hypercholesterolemia
(%)
64,6 62,9 52,5* 0.01
Unstable angina (%) 23,4 23 19* 0.03
Multivessel disease
(%)
59,9 65* 70,6* 0.04
Mean Follow-up(Y) 4,1-2,5 3,8-2,5 3,7-2,0 0.1
Cumulative MACE
Cardiac Death (%) 2,18 4,34 10,44* 0.01
Total MI 6,79 6,47 9,81* 0.02
TVR PCI (%) 5,15 3,21 1,58* 0.01
TVR CABG(%) 1,39 1,04 0 0.3
TVR(%) 6,33 4,13 1,58* 0.01
MACE (%) 22,6 21,0 24,0* 0.05
Conclusions: DES in octogenarians have a higher incidence of MACE(24%) due to
higher periprocedure MI and mortality rate and as compared to younger patients in a long
term follow-up. However, this incidence is far lower than the observed in the historical
series with BMS and CABG in the same population.
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Background: Stenting in small coronary artery and long lesions has been known for high
rates of clinical events. There has been no study comparing angiographic and long-term
clinical outcomes among stable angina patients with sirolimus-(SES,n285), paclitaxel-
(PES,n52), zotarolimus-(ZES,n93), and everolimus-eluting stent (EES,n170) im-
plantation in small coronary target vessels and long lesions.
Methods: Propensity matching was performed among 4 cohort groups, and coronary
lesions with reference diameter2.75mm and lesion length28mm were included. Late
loss and rates of in-stent restenosis at 9-month follow-up were compared, and major
adverse cardiovascular events(MACEs) such as all-cause death, non-fatal myocardial
infarction, stroke, and target lesion revascularization(TLR) were compared during the
3-year follow-up.
Results: Late loss was significantly lower in the EES group when compared with the PES
and ZES groups (0.340.14mm, 0.600.15mm 0.650.16mm, respectively, p0.05).
Rate of TLR was significantly lower in the in the EES group when compared with the
SES, PES and ZES groups (2.1%, 9.8%, 11.8%, 8.4%,respectively). Rates of MACE
during the 3-year follow-up were significantly lower in the EES. (Figure)
TUESDAY, OCTOBER, 23, 8:00 AM–10:00 PMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stents B187
P
O
ST
E
R
S
